510(k) SUMMARY

Submitter Information:

TOTOKU ELECTRIC CO., LTD.

300 Oya, Ueda

Nagano 386-0192 Japan

Contact Person:

Mikio Hasegawa, General Manager

Email: hasegawam@totoku.co.jp

Tel:+81.268.34.5469 Fax:+81.268.34.5548

Date Prepared:

March 17, 2008

Device Name: 21.3-inch (54 cm) 2M Color LCD Monitor CCL254i2 (CDL2125A)

Common Name: CCL254i2, CDL2125A

Classification Name: Class II

(Part 892 Radiology Devices

Sec. 892.2050 Picture Archiving and Communication System)

Predicate Device: 2M Color LCD Monitor CDL2120A (CCL252i2) (K063199)

Device Description:

CCL254i2 (CDL2125A) is a 21.3-inch (54cm) 2 megapixcel Color LCD monitor that supports DVI video signal and provides UXGA (1200 x 1600) resolution for both landscape and portrait display.

Indended Use:

21.3-inch (54cm) 2M Color LCD Monitor CCL254i2 (CDL2125A) is intended to be used in displaying and viewing medical images for diagnosis by trained medical practitioners. It is not meant to be

used for digital mammography.

Substantial Equivalence:

CCL254i2 (CDL2125A) shares the same characteristics with our predicate device CCL252i2 (CDL2120A) (K063199) except for power supply, front bezel, frame, fan, PCB and LCD screen.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN - 4 2008

Mr. Mikio Hasegawa General Manager TOTOKU ELECTRIC CO., Ltd. Intelligent Devices and Solutions Division 300 Oya, Ueda, Nagano 386-0192 JAPAN

Re: K081055

Trade/Device Name: 21.3-inch (54 cm) 2M Color LCD Monitor CCL254i2 (CDL2125A)

Regulation Number: 21 CFR 892.2050

Regulation Name: Picture archiving and communications system

Regulatory Class: II Product Code: LLZ Dated: April 2, 2008 Received: April 14, 2008

Dear Mr. Hasegawa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876 xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Nancy C. Brogdon

Director, Division of Reproductive,

Nancy CBrogdon

Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

•		254i2 (CDL2125A) is to be used
		osis by trained medical practitioners.
is not meant to be used in dig	iitai mammograpity	'ı
		•
•		
Prescription Use	AND/OR	Over-The-Counter Use
(Part 21 CFR 801 Subpart D)	•	(21 CFR 807 Subpart C)
(a) E) CE SO NOT MOTE BELOW	urino inic coliti	AULE ON ANOTHER PAGE OF MEEDER)
(PLEASE DO NOT WRITE BELOV	V THIS LINE-CONTI	NUE ON ANOTHER PAGE OF NEEDED)
Concurrence of	CDRH, Office of De	vice Evaluation (ODE)
		, ,
· ·		
		•

Division of Reproductive, Abdominal and

(Division Sign-Off)

Radiological Devices 510(k) Number ____

510(k) Number: Not Known